Free Trial
OTCMKTS:SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Q4 2025 Earnings Results & Report

Shionogi & Co., Ltd. Unsponsored ADR logo
$9.95 +0.09 (+0.86%)
As of 11:10 AM Eastern

Shionogi & Co., Ltd. Unsponsored ADR missed analyst expectations on both earnings and revenue in its Q4 2025 results, released May 12, 2025. The company reported EPS of $0.14 versus the $0.1654 consensus estimate, while revenue of $721.77 million fell short of the $824.23 million estimate by $102.45 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Shionogi & Co., Ltd. Unsponsored ADR EPS Results

Actual EPS
$0.14
Consensus EPS
$0.1654
Beat/Miss
Missed by -$0.0254
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Shionogi & Co., Ltd. Unsponsored ADR Revenue Results

Actual Revenue
$721.77 million
Expected Revenue
$824.23 million
Beat/Miss
Missed by -$102.45 million
YoY Revenue Growth
N/A

Upcoming Earnings

Shionogi & Co., Ltd. Unsponsored ADR's next earnings date is estimated for Friday, January 29, 2027, based on past reporting schedules.

Conference Call Resources

Shionogi & Co., Ltd. Unsponsored ADR Q4 2025 Earnings FAQ

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) reported earnings of $0.14 per share for Q4 2025, missing the consensus estimate of $0.1654. The report was announced on Monday, May 12, 2025.

Shionogi & Co., Ltd. Unsponsored ADR reported revenue of $721.77 million for Q4 2025, against a consensus estimate of $824.23 million.

Shionogi & Co., Ltd. Unsponsored ADR's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for Shionogi & Co., Ltd. Unsponsored ADR on the company's earnings history page.

Shionogi & Co., Ltd. Unsponsored ADR Earnings Headlines

SHIONOGI & CO LTD
Why my scanner is $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Shionogi & Co., Ltd. Unsponsored ADR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd. Unsponsored ADR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. Unsponsored ADR and other key companies, straight to your email.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker.

The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.

Shionogi serves patients in Japan and international markets through its own operations and collaborations with other pharmaceutical companies. Its partnerships have supported the development and commercialization of medicines in areas including HIV treatment.

View Shionogi & Co., Ltd. Unsponsored ADR Profile